Robert Celt
New Member
There's no debating the wild ride the marijuana industry has had since legalization for recreational use went live in 2014. Now two years later we are faced with a very critical time in the country's history not only because many other states are adopting legalization initiatives but also because this is an election year.
Marijuana Policies from people like Bernie Sanders, Hilary Clinton, and even Donald Trump have all been up for discussion in recent party debates. Recreational marijuana and medical marijuana legalization have been major hot button items on the docket and for good reason. Not only is marijuana being found to have very positive health benefits as a form of therapy for certain ailments but also it's been a huge cash crop for the government via taxes.
With so much on the line this year for medical and recreational cannabis, looking into this space early may be important especially when we'll be talking about it in 10 months when "election season" is at a fever pitch. Being that it's still January, what better to become familiar with this industry and its companies than right now? Several marijuana stocks that have been gaining momentum this year include CLS Holdings, Inc. (OTCQB: CLSH), PharmaCyte Biotech, Inc. (OTCQB: PMCB), and Terra Tech Corp. (OTCQX: TRTC).
CLS Holdings, Inc focuses on extraction and conversion of cannabinoids. CLS stands for "Cannabis Life Sciences," in recognition of the Company's patent pending proprietary method of extracting various cannabinoids from the marijuana plant and converting them into a higher quality and quantity of products. The Company's business model includes licensing operations, processing operations, processing facilities, sale of products, brand creation and consulting services. Since the beginning of the year, shares of CLSH have begun to climb back from previous lows of $0.77.
Previous to this, the stock had been trading in a price range north of $1.30 and as of January it has since made strong headway back toward that direction after hitting highs earlier this week of $1.18. At the end of 2015, CLSH announced that an affiliate of its licensing partner, Picture Rock Holdings, a Colorado limited liability company, will operate a grow in Denver, Colorado for Picture Rock, and it received its certificate of occupancy for the grow on October 5, 2015. According to the company, CLSH had the end of November slated as the anticipated period that it would be planting at the grow. Picture Rock is expected to start processing its first harvest in the first quarter of 2016.
PharmaCyte Biotech, Inc. has seen a rebound in price since hitting lows earlier this month of $0.0385. Just this week the company announced that its Chief Executive Officer, Kenneth L. Waggoner, and its Chief Operating Officer, Dr. Gerald W. Crabtree, recently met with principals of Translational Drug Development at TD2's facilities in Scottsdale, Arizona. PharmaCyte stated that this meeting was held to discuss several key topics relating to the Company's upcoming clinical trial in pancreatic cancer. PMCB has contracted with TD2 to be the lead Contract Research Organization to prepare for and conduct PharmaCyte's clinical trial in pancreatic cancer. As of Wednesday's close, shares of PMCB remain over 60% higher than early January lows.
Terra Tech Corp. announced revenue guidance last Friday. In the release, the Company announced revenue guidance of $20 - $22 million for the full year 2016. The anticipated jump in year-over-year revenue is expected to be driven in a large part by sales from the Company's latest acquisition, Blum Oakland, an established, retail medical cannabis dispensary in Oakland, CA, as well as continued growth of the IVXX brand throughout the California and Nevada markets.
"We are greatly encouraged by the ongoing changes in public policy, including California's recently enacted Marijuana Regulation and Safety Act, which will help increase our total addressable market. As we enter 2016, we aim to pursue an aggressive M&A strategy to scale the business and enhance our offering," stated TRTC CEO Derek Peterson. Recent January highs show TRTC rising more than 90% from the first trading day of the year, after hitting highs earlier this month of $0.183.
News Moderator: Robert Celt 420 MAGAZINE ®
Full Article: Presidential Elections Put Cannabis & Cannabis Stocks To Watch, Center Stage In 2016
Author: Staff
Contact: StockHouse
Photo Credit: WatchDogWire
Website: StockHouse
Marijuana Policies from people like Bernie Sanders, Hilary Clinton, and even Donald Trump have all been up for discussion in recent party debates. Recreational marijuana and medical marijuana legalization have been major hot button items on the docket and for good reason. Not only is marijuana being found to have very positive health benefits as a form of therapy for certain ailments but also it's been a huge cash crop for the government via taxes.
With so much on the line this year for medical and recreational cannabis, looking into this space early may be important especially when we'll be talking about it in 10 months when "election season" is at a fever pitch. Being that it's still January, what better to become familiar with this industry and its companies than right now? Several marijuana stocks that have been gaining momentum this year include CLS Holdings, Inc. (OTCQB: CLSH), PharmaCyte Biotech, Inc. (OTCQB: PMCB), and Terra Tech Corp. (OTCQX: TRTC).
CLS Holdings, Inc focuses on extraction and conversion of cannabinoids. CLS stands for "Cannabis Life Sciences," in recognition of the Company's patent pending proprietary method of extracting various cannabinoids from the marijuana plant and converting them into a higher quality and quantity of products. The Company's business model includes licensing operations, processing operations, processing facilities, sale of products, brand creation and consulting services. Since the beginning of the year, shares of CLSH have begun to climb back from previous lows of $0.77.
Previous to this, the stock had been trading in a price range north of $1.30 and as of January it has since made strong headway back toward that direction after hitting highs earlier this week of $1.18. At the end of 2015, CLSH announced that an affiliate of its licensing partner, Picture Rock Holdings, a Colorado limited liability company, will operate a grow in Denver, Colorado for Picture Rock, and it received its certificate of occupancy for the grow on October 5, 2015. According to the company, CLSH had the end of November slated as the anticipated period that it would be planting at the grow. Picture Rock is expected to start processing its first harvest in the first quarter of 2016.
PharmaCyte Biotech, Inc. has seen a rebound in price since hitting lows earlier this month of $0.0385. Just this week the company announced that its Chief Executive Officer, Kenneth L. Waggoner, and its Chief Operating Officer, Dr. Gerald W. Crabtree, recently met with principals of Translational Drug Development at TD2's facilities in Scottsdale, Arizona. PharmaCyte stated that this meeting was held to discuss several key topics relating to the Company's upcoming clinical trial in pancreatic cancer. PMCB has contracted with TD2 to be the lead Contract Research Organization to prepare for and conduct PharmaCyte's clinical trial in pancreatic cancer. As of Wednesday's close, shares of PMCB remain over 60% higher than early January lows.
Terra Tech Corp. announced revenue guidance last Friday. In the release, the Company announced revenue guidance of $20 - $22 million for the full year 2016. The anticipated jump in year-over-year revenue is expected to be driven in a large part by sales from the Company's latest acquisition, Blum Oakland, an established, retail medical cannabis dispensary in Oakland, CA, as well as continued growth of the IVXX brand throughout the California and Nevada markets.
"We are greatly encouraged by the ongoing changes in public policy, including California's recently enacted Marijuana Regulation and Safety Act, which will help increase our total addressable market. As we enter 2016, we aim to pursue an aggressive M&A strategy to scale the business and enhance our offering," stated TRTC CEO Derek Peterson. Recent January highs show TRTC rising more than 90% from the first trading day of the year, after hitting highs earlier this month of $0.183.
News Moderator: Robert Celt 420 MAGAZINE ®
Full Article: Presidential Elections Put Cannabis & Cannabis Stocks To Watch, Center Stage In 2016
Author: Staff
Contact: StockHouse
Photo Credit: WatchDogWire
Website: StockHouse
